A Study of Therapeutic Equivalence of mometasone cream and Elomet cream in eczema

Phase 2

• Conditions: Preventive or screening interventions; Mometasone cream, elomet cream, eczema

• Registration Number: TCTR20220210004
• Lead Sponsor: Zuellig Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-10
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Age 18-60 years old
2. Diagnosis of eczema for example irritant contact dermatitis, allergic contact dermatitis, atopic dermatitis, seborrheic dermatitis and nummular eczema
3. New lesion of eczema or recurrent eczema that stop topical treatments for 2 weeks or stop systemic treatments for 4 weeks
4. Can follow up at day 0, 7, 14, 21 and 28

Exclusion Criteria

1. Use topical treatments within 2 weeks
2. Use systemic treatments or immunosuppressive drugs within 4 weeks
3. Have others skin infections
4. Pregnancy or breast feeding
5. Allergy to steroid or other components in cream that we use in the research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of eczema at day 0,7,14,21,28 after the intervention Total sign and symptom (TSS) score

Secondary Outcome Measures

Name	Time	Method
Erythema index at day 0,7,14,21,28 after the intervention Calorimeter,Side effects at day 7,14,21,28 after the intervention Patient reported outcome using a questionnaire interview,Patient Satisfaction at day 7,14,21,28 after the intervention visual analogue scale (VAS)